{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034710","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.535787+00:00","generated_at":"2026-06-04T10:16:37.419099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nkarta reports FY2023 net loss $117.5M; deprioritizes NKX101, advances NKX019 in autoimmune","bullets":["FY2023 net loss of $117.5M ($2.40 per basic/diluted share).","Year-end cash, equivalents & investments $250.9M; expected to fund operations into 2026.","NKX019 lupus nephritis trial on track to dose first patient in H1 2024.","NKX101 AML program deprioritized after CR/CRi rate 5/20 vs 4/6 in first 6 patients.","NKX019 compressed dosing cohort in NHL; preliminary data expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034710","json":"https://secwatch.observer/filing/0000950170-24-034710.json","markdown":"https://secwatch.observer/filing/0000950170-24-034710.md","text":"https://secwatch.observer/filing/0000950170-24-034710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/0000950170-24-034710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/nktx-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:16:37.419099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f9f03a6de3f57c2a3e488c018e8bcb7d365eda0","claim":"Nkarta, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 21, 2024, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/0000950170-24-034710-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}